Contact Allergy to Preservatives and Emulsifiers in Patients With or Without Atopic Dermatitis

Allergic DiseasesFurther Publications Dermatology

Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta-Analysis

Contact Dermatitis

Jensen MB, Isufi D, Larsen CK, Schwensen JFB, Alinaghi F, Johansen JD

doi: 10.1111/cod.14784

Atopic DermatitisAllergic Diseases

Impact of Food Allergy on the Atopic March Progression from Atopic Dermatitis in Early Childhood to Other Atopic Disorders at School Age

J Allergy Clin Immunol Pract

Zeiger RS, Schatz M, Zhou B, Stern JA, Li Q, Basrai S, Stanford RH, Shams M, Avella H, Subramaniam A, Chen W

doi: 10.1016/j.jaip.2025.05.001

Allergic Diseases

Trends in Contact Allergy to Preservatives From 2014 to 2023: Benzisothiazolinone on the Rise

Contact Dermatitis

Søgaard R, Kursawe Larsen C, Johansen JD, Schwensen JFB

doi: 10.1111/cod.14818

Atopic Dermatitis

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

J Allergy Clin Immunol Pract

Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T, FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group

doi: 10.1016/j.jaip.2024.12.001

Atopic Dermatitis

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

JAMA Dermatol

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY

doi: 10.1001/jamadermatol.2025.1578

Atopic DermatitisAllergic Diseases

Skin barrier as a target for the prediction, prevention, and treatment of atopic dermatitis and food allergy in infancy

Pediatr Allergy Immunol

Kim J, Shin S, Kim BE, Ahn K

doi: 10.1111/pai.70238

Atopic Dermatitis

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

JAMA Ophthalmol

Chu YY, Sung CH, Lin YS, Ho CH, Chen YC, Lee WA, Kuo SC

doi: 10.1001/jamaophthalmol.2025.0366

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Related content

Prevalence of Contact Allergy to Neomycin in Dermatitis Patients: A Systematic Review and Meta-Analysis

Impact of Food Allergy on the Atopic March Progression from Atopic Dermatitis in Early Childhood to Other Atopic Disorders at School Age

Trends in Contact Allergy to Preservatives From 2014 to 2023: Benzisothiazolinone on the Rise

Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Skin barrier as a target for the prediction, prevention, and treatment of atopic dermatitis and food allergy in infancy

Risk of Developing Pediatric Uveitis Among Patients With Early-Onset Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials